Infections Causing Pulmonary Hemorrhage
Invasive aspergillosis is the most critical infection causing pulmonary hemorrhage in immunocompromised patients, particularly those with neutropenia, where it manifests as devastating hemorrhagic infarction that is almost universally fatal without prompt antifungal therapy 1.
Primary Infectious Causes by Clinical Context
Immunocompromised/Neutropenic Patients
Aspergillus species represent the dominant threat for life-threatening pulmonary hemorrhage in this population. Without adequate therapy, invasive pulmonary aspergillosis progresses to hemorrhagic infarction or necrotizing pneumonia 1. The hemorrhagic nature occurs because Aspergillus invades blood vessels, causing thrombosis and tissue necrosis. Early initiation of voriconazole (the preferred agent over amphotericin B formulations) is warranted even with suspected—not just confirmed—invasive aspergillosis 1.
Mucorales (causing mucormycosis) should also be considered in febrile neutropenic patients with lung infiltrates, particularly those with breakthrough fungal infection on azole prophylaxis 2.
Community-Acquired Infections
Staphylococcus aureus, particularly community-acquired MRSA with Panton-Valentine leukocidin (PVL) toxin, causes necrotizing and hemorrhagic pneumonia with potential for pneumothorax, empyema, and ventilatory failure 3. This represents an emerging cause of severe pulmonary hemorrhage in previously healthy individuals.
Group A Streptococcus can cause severe intraalveolar hemorrhage leading to sudden death from asphyxia, presenting initially as fever and sore throat followed by rapid progression to hemoptysis, cyanosis, and dyspnea 4.
Leptospira species cause leptospirosis-associated pulmonary hemorrhagic syndrome (LPHS) with approximately 50% mortality, typically occurring within 72 hours of symptom onset. Patients present with cough, chest pain, dyspnea, and massive pulmonary hemorrhage 5. This is particularly relevant in tropical/subtropical regions with poor sanitation.
Hospital-Acquired and Healthcare-Associated Infections
Pseudomonas aeruginosa and Acinetobacter species are associated with increased mortality when causing bacteremic pneumonia, particularly in mechanically ventilated patients 6. These gram-negative organisms are more common in late-onset hospital-acquired pneumonia (≥5 days) and carry higher risk of hemorrhagic complications.
MRSA in the hospital setting causes severe pneumonia with potential hemorrhagic features, especially in diabetics, head trauma patients, and ICU patients 6.
Additional Infectious Causes
Mycoplasma pneumoniae, while typically causing mild disease, can rarely cause diffuse alveolar hemorrhage even in immunocompetent patients 7. This requires lower respiratory tract sampling for accurate diagnosis as throat swabs may be falsely negative.
Respiratory Syncytial Virus (RSV) can cause pulmonary hemorrhage as a complication of bronchiolitis, particularly in premature infants requiring mechanical ventilation 8.
Dengue virus can present with predominant respiratory symptoms and alveolar hemorrhage, requiring differentiation from other viral respiratory syndromes 9.
Legionella pneumophila should be considered in hospitalized patients with severe pneumonia, particularly when water supplies are colonized 10.
Critical Diagnostic Approach
For neutropenic patients with lung infiltrates and suspected hemorrhage:
- Obtain thoracic CT scan within 24 hours 2
- Perform bronchoscopy with BAL within 24 hours of documented infiltrates 2
- Test BAL for Aspergillus galactomannan (threshold ≥1.0 in BAL) 2
- Send BAL for bacterial culture, fungal culture, and molecular testing (FilmArray) 7
- Initiate empiric mold-active antifungal therapy (voriconazole or liposomal amphotericin B) immediately without awaiting culture results 2
For community-acquired cases with hemorrhage:
- Consider PVL-positive MRSA in previously healthy patients with necrotizing features
- Evaluate for leptospirosis in endemic areas with appropriate exposure history
- Blood cultures are essential as bacteremic pneumonia carries higher mortality 6
Key Pitfall
Do not delay antifungal therapy in neutropenic patients awaiting diagnostic confirmation—invasive aspergillosis with hemorrhagic infarction is almost universally fatal without prompt treatment, and early empiric therapy significantly improves survival 1, 2.